



PROCLAMATION

WHEREAS, lung cancer is the leading cause of cancer death among men and women in the United States and Washington, accounting for more deaths than colon cancer, breast cancer, and prostate cancer combined; (1-2)

WHEREAS, according to the Centers for Disease Control, there were 22,277 new lung cancer cases and 14,110 deaths because of lung cancer between 2016 and 2020 in Washington (2)

WHEREAS, the 5-year survival rate for localized lung cancer is ~60%, yet only ~24% of lung cancers are diagnosed at this stage; (1)

WHEREAS, screening for lung cancer for high-risk individuals using low-dose computed tomography can lead to the earlier detection of lung cancer and save lives, reducing the mortality by 20% when compared to screening by chest x-ray in the National Lung Screening Trial (3) and reducing the risk of death at 10 years by 24% in men and 33% in women as demonstrated by another large randomized trial; (4)

WHEREAS, funding for lung cancer research trails far behind funding for research of many other cancers, and additional research is needed in early diagnosis, screening, and treatment for lung cancer as well as in lung cancer affecting women and lung cancer health disparities;

WHEREAS, lung cancer incidence is decreasing twice as fast in men as it is in women, each year more women die from lung cancer than breast cancer and by 2035, more women will die from lung cancer than men; (6-7)

WHEREAS, African Americans have the highest lung cancer incidence and mortality of all races, and disparities in lung cancer screening, diagnosis, treatment, and mortality are well characterized among African Americans and other racial minorities. (8)

WHEREAS, lung cancer in individuals who never smoked is the 7th leading cause of cancer-related death and accounts for 17,000-26,000 deaths in the US every year (7), 60-70% of individuals diagnosed with lung cancer who never smoked are women (9,10), and the proportion of lung cancers diagnosed in people who never smoked is increasing in the US; (10,11). Whereas radon is the leading cause of lung cancer among individuals who never smoked and the second leading cause of lung cancer overall. (12-13)

WHEREAS, the stigma surrounding lung cancer creates barriers to early diagnosis, treatment, and funding for research, has a detrimental impact on the quality of life of people diagnosed with lung cancer, and hinders awareness of and research into lung cancer risk factors other than smoking;

WHEREAS, lung cancer research is leading to breakthroughs in the identification of genetic alterations associated with lung cancer and in the development of lung cancer treatments, including immunotherapies and targeted therapies; (14-17)

WHEREAS, organizations working in Washington such as the American Lung Cancer Screening Initiative and Women's Lung Cancer Forum, are committed to educating about lung cancer and lung cancer screening and working to increase lung cancer screening rates in Washington.

NOW, THEREFORE, I, Keith Scully, Mayor of the City of Shoreline, on behalf of the Shoreline City Council, do hereby proclaim the month of November as

LUNG CANCER AWARENESS MONTH

in the City of Shoreline and recognize the need for research in lung cancer affecting women and lung cancer health disparities, and encourage all citizens to learn about lung cancer and early detection through lung cancer screening.




Keith Scully, Mayor

- (1) "Cancer of the Lung and Bronchus - Cancer Stat Facts." SEER, seer.cancer.gov/statfacts/html/lungb.html.
- (2) "United States Cancer Statistics: Data Visualizations." Center for Disease Control, <https://gis.cdc.gov/Cancer/USCS/DataViz.html>.
- (3) National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med.* 2011;365(5):395-409. doi:10.1056/NEJMoa1102873
- (4) de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. *N Engl J Med.* 2020;382(6):503-513. doi:10.1056/NEJMoa1911793
- (5) Siegel, R. L.; Miller, K. D.; Jemal, A., Cancer statistics, 2020. *CA: A Cancer Journal for Clinicians* 2020, 70 (1), 7-30.
- (6) Jeon, J.; Holford, T. R.; Levy, D. T.; Feuer, E. J.; Cao, P.; Tam, J.; Clarke, L.; Clarke, J.; Kong, C. Y.; Meza, R., Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. *Ann Intern Med* 2018, 169 (10), 684-693.
- (7) Rivera, G. A.; Wakelee, H., Lung Cancer in Never Smokers. *Adv Exp Med Biol* 2016, 893, 43-57.
- (8) Rivera, M. P.; Katki, H. A.; Tanner, N. T.; Triplett, M.; Sakoda, L. C.; Wiener, R. S.; Cardarelli, R.; Carter-Harris, L.; Crothers, K.; Fathi, J. T.; Ford, M. E.; Smith, R.; Winn, R. A.; Wisnivesky, J. P.; Henderson, L. M.; Aldrich, M. C., Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society Statement. *American Journal of Respiratory and Critical Care Medicine* 2020, 202 (7), e95-e112.
- (9) Korpany, G. J.; Kamel-Reid, S.; Pintilie, M.; Hwang, D. M.; Zer, A.; Liu, G.; Leigh, N. B.; Feld, R.; Siu, L. L.; Bedard, P. L.; Tsao, M.-S.; Shepherd, F. A., Lung cancer in never smokers from the Princess Margaret Cancer Centre. *Oncotarget* 2018, 9 (32), 22559-22570.
- (10) Pelosof, L.; Ahn, C.; Gao, A.; Horn, L.; Madrigales, A.; Cox, J.; McGavic, D.; Minna, J. D.; Gazdar, A. F.; Schiller, J., Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. *Journal of the National Cancer Institute* 2017, 109 (7), djw295.
- (11) Toh, C. K.; Ong, W. S.; Lim, W. T.; Tan, D. S.; Ng, Q. S.; Kanesvaran, R.; Seow, W. J.; Ang, M. K.; Tan, E. H., A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved Survival. *Clin Lung Cancer* 2018, 19 (5), e539-e550.
- (12) Riudavets, M.; Garcia de Herreros, M.; Besse, Mezquita, L., Radon and Lung Cancer: Current Trends and Future Perspectives, 2022. *Cancers* 2022, 14 (13).
- (13) "Health Risk of Radon." United States Environmental Protection Agency, <https://www.epa.gov/radon/health-risk-radon#:~:text=Radon%20is%20the%20number%20one,people%20who%20have%20never%20smoked>.
- (14) Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. *N Engl J Med.* 2022;387(2):120-131. doi:10.1056/NEJMoa2204619
- (15) Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. *N Engl J Med.* 2022;386(21):1973-1985. doi:10.1056/NEJMoa2202170
- (16) Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. *Lancet Lond Engl.* 2021;398(10308):1344-1357. doi:10.1016/S0140-6736(21)02098-5
- (17) Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. *N Engl J Med.* 2020;383(18):1711-1723. doi:10.1056/NEJMoa2027071